Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Satellos Bioscience Inc (QB) | MSCLF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.36 | 07:02:13 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.36 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.22046 - 0.5701 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.36 | USD |
Satellos Bioscience Inc (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 56.4M | 112.79M | 180.08M | 0 | -15.89M | -0.14 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Satellos Bioscience (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MSCLF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.3474 | 0.36 | 0.32 | 0.3302605 | 16,400 | 0.0126 | 3.63% |
| 1 Month | 0.3193 | 0.368 | 0.2974 | 0.3254195 | 12,103 | 0.0407 | 12.75% |
| 3 Months | 0.4973 | 0.4973 | 0.2974 | 0.3617674 | 13,886 | -0.1373 | -27.61% |
| 6 Months | 0.37155 | 0.5701 | 0.2974 | 0.3821572 | 16,563 | -0.01155 | -3.11% |
| 1 Year | 0.41875 | 0.5701 | 0.22046 | 0.3708261 | 13,609 | -0.05875 | -14.03% |
| 3 Years | 0.928 | 1.00 | 0.0035 | 0.3863052 | 14,655 | -0.568 | -61.21% |
| 5 Years | 0.928 | 1.00 | 0.0035 | 0.3863052 | 14,655 | -0.568 | -61.21% |
Satellos Bioscience (QB) Description
| Satellos is a biotechnology company dedicated to developing life-changing medicines to treat degenerative muscle conditions. Satellos' lead program is focused on developing an oral therapeutic drug intended to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. This therapeutic approach represents a potential disease modifying treatment for Duchenne and other dystrophies, offering new hope to patients. To expand programs to other degenerative muscle conditions or disorders, Satellos has created a proprietary discovery platform, MyoReGenX, which is utilized to identify disease situations where deficits in muscle stem cell polarity and regeneration occur and are amenable to therapeutic treatment. |
